Evenity (Romosozumab) Manufacturer Copay Program

What the Evenity Copay Program Covers

Amgen's copay assistance card offsets patient cost-sharing for commercially insured individuals who receive a valid prescription for Evenity. The program reimburses the difference between the patient's copay or coinsurance and a $5 floor, up to a maximum annual benefit that Amgen adjusts periodically. As of 2026, the cap has been reported at $25,000 per calendar year, which covers most patients' full 12-dose course given typical specialty-tier coinsurance rates of 20-33% 1.

Enrollment requires proof of commercial insurance, a valid U.S. Prescription, and confirmation that the patient is not enrolled in any federal or state healthcare program. The card is typically activated through the prescribing physician's office or specialty pharmacy 2. Patients should verify current terms directly with Amgen, as copay program structures change frequently.

The program applies exclusively to Evenity's approved indication: treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy 3.

Why Evenity Costs $1,825 Per Injection

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a glycoprotein produced by osteocytes that suppresses bone formation. This mechanism is unique among osteoporosis therapies. The FRAME trial (N=7,180) demonstrated that romosozumab 210 mg monthly for 12 months followed by denosumab reduced new vertebral fracture incidence by 73% compared to placebo-then-denosumab at 24 months (0.6% vs 2.5%, P<0.001) 4.

Manufacturing a monoclonal antibody at clinical scale requires mammalian cell culture systems, extensive purification, and cold-chain logistics. Each monthly dose consists of two 105 mg/1.17 mL prefilled syringes administered subcutaneously. The biologic complexity, patent exclusivity through at least 2029, and absence of biosimilar competition maintain the current price point 5.

The ARCH trial (N=4,093) compared romosozumab-to-alendronate versus alendronate alone and found a 48% lower risk of new vertebral fracture at 24 months in the romosozumab-first group (4.0% vs 7.7%, P<0.001) 6. These efficacy data support formulary inclusion but also justify premium pricing from the manufacturer's perspective.

Step-by-Step Enrollment in the Copay Card

The process involves three stages. First, the prescribing clinician submits a prior authorization to the patient's insurer documenting high fracture risk. The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy as first-line for patients with very high fracture risk, defined as recent fracture within 12 months, fractures while on approved osteoporosis therapy, multiple fractures, T-score below -3.0, or high FRAX probability 7.

Second, once insurance approval is confirmed, the physician's office or patient contacts Amgen's support hub (typically called Amgen Assist 360) to register for the copay card. Registration requires the insurance explanation of benefits or prior authorization approval letter, the patient's date of birth, and the prescribing physician's NPI number 8.

Third, the specialty pharmacy or physician office (for buy-and-bill arrangements) processes the copay card at the point of dispensing. The card functions as a secondary payer, reimbursing whatever the primary insurer does not cover minus the patient's $5 responsibility. Patients should confirm activation before their first dose appointment to avoid unexpected bills.

Insurance Coverage Field for Romosozumab

Most large commercial insurers cover Evenity on specialty tier with prior authorization. Coverage criteria generally mirror the FDA label plus additional utilization management: documented T-score of -2.5 or below at the hip or spine, trial or contraindication to at least one oral bisphosphonate, and documented high fracture risk 9.

Medicare Part B covers romosozumab under the buy-and-bill pathway because it is administered by a healthcare provider. Beneficiaries are responsible for 20% coinsurance after their Part B deductible, which amounts to approximately $365 per injection or $4,380 over the 12-month course. The manufacturer copay card cannot be applied to Medicare patients per federal anti-kickback statute 10.

For Medicare patients, supplemental Medigap plans (Plans C, F, or G) may cover part or all of the 20% coinsurance. Medicare Advantage plans vary widely; some require step therapy through teriparatide or abaloparatide first. The American Association of Clinical Endocrinology (AACE) 2020 guidelines position romosozumab as appropriate initial therapy for very high-risk patients regardless of prior bisphosphonate use 11.

Amgen Safety Net Foundation for Uninsured Patients

Patients without any insurance coverage may qualify for free Evenity through the Amgen Safety Net Foundation, a 501(c)(3) patient assistance program. Eligibility is income-based, typically requiring household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026). The application requires tax documentation, a signed physician statement of medical necessity, and proof of uninsured status 12.

Approval grants free drug supply for the full 12-month treatment course. Patients must reapply annually if treatment duration changes or if they gain insurance coverage mid-treatment. Processing time is typically 5-10 business days after complete application submission.

For underinsured patients whose copay exceeds the copay card maximum or who have restrictive plan designs, Amgen's support team can sometimes identify bridge solutions or connect patients to independent charitable foundations. The HealthWell Foundation and the National Organization for Rare Disorders occasionally fund osteoporosis-related grants, though availability fluctuates quarterly 13.

Comparing Romosozumab Cost to Alternative Anabolic Agents

Teriparatide (Forteo) carries a wholesale acquisition cost of approximately $3,600 per month for 24 months of therapy, totaling roughly $86,400 at list price. Generic teriparatide became available in 2024, reducing the generic price to approximately $1,200-1,800 per month 14. Abaloparatide (Tymlos) costs approximately $2,900 per month for 18-24 months.

Romosozumab's 12-month course at $21,900 total is therefore less expensive on a per-course basis than branded teriparatide ($86,400) and comparable to abaloparatide ($52,200-69,600 over 18-24 months). The shorter treatment duration is clinically relevant because the FRAME extension showed that bone mineral density gains from 12 months of romosozumab were maintained and augmented when patients transitioned to denosumab 15.

A 2022 cost-effectiveness analysis published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate was cost-effective versus oral alendronate alone at a willingness-to-pay threshold of $150,000 per quality-adjusted life year in women aged 70+ with T-scores below -3.0 and prior fracture 16.

The Cardiovascular Safety Consideration and Its Impact on Access

The ARCH trial identified a numerical imbalance in adjudicated major adverse cardiovascular events (MACE): 2.5% in the romosozumab group versus 1.9% in the alendronate group over 12 months of active treatment. This led to a boxed warning stating that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death, and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year 17.

This boxed warning affects insurance coverage decisions. Some plans require documentation that the patient has no history of cardiovascular events within 12 months and may require cardiac risk stratification. The requirement adds a step to prior authorization but does not typically prevent coverage for eligible patients. The AACE guideline committee noted that absolute cardiovascular risk in ARCH was low and the finding may be confounded by alendronate's potential cardioprotective effects rather than a true romosozumab hazard 18.

A post-hoc analysis of FRAME, which compared romosozumab to placebo rather than alendronate, found no significant difference in MACE (0.6% vs 0.6% over 12 months), supporting the interpretation that the ARCH signal may reflect comparator benefit rather than romosozumab harm 19.

Tips for Maximizing Coverage Approval

Prior authorization success rates improve with thorough documentation. Include the following in every submission: DXA scan results with numeric T-scores, FRAX 10-year fracture probability calculations, history of fragility fractures with imaging dates, documentation of bisphosphonate trial or intolerance, and cardiovascular clearance 20.

If the initial prior authorization is denied, file a peer-to-peer review request within 72 hours. Cite the Endocrine Society and AACE guidelines positioning anabolic therapy first-line for very high-risk patients. Reference the patient's specific fracture probability and note that delaying treatment during appeal increases fracture risk by approximately 3-5% per year in this population 21.

For Medicare Advantage denials, patients retain the right to request an Integrated Determination, which routes the case to an independent review entity. External review overturn rates for specialty biologics with strong guideline support have been reported at 40-60% in published audits 22.

Sequence Therapy After Romosozumab and Cost Implications

The romosozumab label limits treatment to 12 monthly doses. Bone mineral density gains reverse rapidly if no antiresorptive agent follows. The DATA-Switch extension demonstrated that patients transitioning from romosozumab to denosumab continued gaining BMD, reaching +17.5% at the spine and +8.5% at the total hip over 36 months total 23.

This mandates planning for post-romosozumab antiresorptive costs at the outset. Denosumab (Prolia) costs approximately $1,800 per injection every 6 months and has its own copay card program from Amgen. Oral alendronate is generic at $10-20 per month. The choice between them affects total out-of-pocket over the first 3-5 years of fracture prevention 24.

Prescribers should discuss the full cost trajectory with patients before initiating romosozumab: 12 months of romosozumab (with copay card: ~$60 total patient cost) followed by indefinite antiresorptive therapy. Stopping denosumab without bisphosphonate bridging causes rapid bone loss and rebound vertebral fractures, a phenomenon documented in multiple case series 25.

State-Level Copay Accumulator Protections

Fourteen states plus the District of Columbia have enacted copay accumulator adjustment program (CAAP) reforms that require insurer copay assistance to count toward patient deductibles and out-of-pocket maximums. In these states, the Amgen copay card effectively zeros out the patient's annual specialty drug cost-sharing entirely 26.

In states without CAAP protections, some insurers apply accumulator adjustor programs that prevent manufacturer copay assistance from counting toward the deductible. Patients in these plans may face a "copay cliff" once the manufacturer program's annual cap is exhausted. Verify your plan's accumulator policy in the Summary of Benefits and Coverage document before treatment initiation.

States with confirmed accumulator protections as of 2026 include Arizona, Arkansas, Connecticut, Georgia, Illinois, Kentucky, Louisiana, Maine, New York, North Carolina, Oklahoma, Tennessee, Virginia, and West Virginia. Federal employees under FEHB plans have separate protections under OPM guidance 27.